Nektar Therapeutics (NKTR) Q4 2025 Earnings Call Transcript

AI Briefing

• – Nektar Therapeutics reports Q4 2025 earnings, shares are expected to be impacted by QDNA's clinical hold.
• – QDNA is currently in clinical hold, and its impact on NKTR's financials is uncertain.
• – Nektar Therapeutics is awaiting further information on the clinical hold of QDNA.